What’s Basenese’s “PGB” Stock? Thinkolator Answers Coming Your Way…

New ad for Micro-Cap Advantage hints at huge gains ahead if you buy before November 14 -- what's the story?

By Travis Johnson, Stock Gumshoe, October 14, 2021

The intro to the latest ad from Lou Basenese has it all — tiny company, huge opportunity, mysterious name, and deadline, just about all you need to get readers fired up to pull out their credit card. Here’s his wording:

“Buy ‘PGB’ Now!

“One tiny cokmpany is on track to dominate a $228 billion market…

“Handing early investors a potential ’10-bagger’ opportunity…

“But ONLY if you make one simple move before November 14, 2021”

So what is that mysterious “PGB,” and is there a reason to buy it in the next month? Let’s put the Thinkolator to work and see what we can find. The ad is for Trend Trader Daily’s Micro Cap Advantage, one of Basenese’s more expensive services — it’s being sold at $995, and, to his credit, he does offer a refund if you change your mind in the first 30 days, a reassurance that is becoming rarer among the high-cost services.

And he gets more detailed early on in the ad:

“I currently have $306,380 invested in a single stock.

“This stock currently trades for just $13 or so, about the same price as lunch from a fast-food spot.

“In other words, this stock is dirt cheap — for now.

“Why have I gone in so big on such a tiny little company? Well…

“In the months following November 14th 2021, I predict two things will happen…

“First, this company could receive full approval on the first ever ‘Plug and Play’ cure for ALL diseases…

“And second, this stock could personally hand me over a million dollars in pure profit.”

So that “PGB” reference is an acronym he made up, for Precision-Guided Biologics, and it’s some kind of immunotherapy — which is not brand new, the first experiments in cancer immunotherapy were in the 19th century, but drugs that leverage the body’s immune system are still a fairly new tool in fighting most cancers, and immunotherapy has gotten a lot of attention in the past 5-10 years thanks to the blockbuster success of drugs like Opdivo (from Bristol Myers Squibb) and Keytruda (from Merck)(those are just some prominent examples, there are many others).

Basenese references a couple big winning stocks that work in this “PGB” area as well, to give us a taste of the gains that might be possible…

“Trillium saw its stock spike 188% over the weekend after a massive $2.3 billion buyout offer from Pfizer…

“Or take a look at Arcus Biosciences (RCUS)…

“After entering a deal with Gilead which valued the company at more than $2 billion…

“Its share price soared, handing investors who got ahead of the deal a 528% gain!

….

“A tiny company called Forty Seven, Inc. (FTSV) was acquired by Gilead for $4.9 billion…

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


“Handing early investors a peak gain of 1,605% in less than six months!”

So I guess that’s the dream for our little $13 stock… but what is it? Let’s get to some more clues…

“Its market cap is only around $400 million….

“It’s an early-stage biotech company, with its treatment currently only in the first phase of clinical trials.

“But once it reveals new data at an industry conference on November 14th…

&